| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T24 |
0-12 |
Sentence |
denotes |
Introduction |
| T25 |
13-115 |
Sentence |
denotes |
A novel human coronavirus which is a new strain of RNA viruses was recognized in Wuhan, China, in Dec. |
| T26 |
116-121 |
Sentence |
denotes |
2019. |
| T27 |
122-286 |
Sentence |
denotes |
The novel coronavirus is now officially named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) by International Committee on Taxonomy of Viruses (ICTV). |
| T28 |
287-390 |
Sentence |
denotes |
The pneumonia caused by SARS-CoV-2 has been recently identified as COVID-19 (coronavirus disease 2019). |
| T29 |
391-770 |
Sentence |
denotes |
COVID-19 spread quickly across Hubei Province and other regions of China,1 , 2 also the global alert for COVID-19 has been issued by the World Health Organization (WHO).1 , 2 COVID-19 could induce symptoms including fever, dry cough, dyspnea, fatigue and lymphopenia in patients, and might result in severe acute respiratory syndrome (SARS) and even death in severe cases.1, 2, 3 |
| T30 |
771-1132 |
Sentence |
denotes |
SARS-CoV-2 belongs to the beta-coronavirus 2b lineage in the phylogenetic tree and shares ∼80% identity sequencing with the Bat SARS-like coronavirus and the original SARS epidemic virus.4 , 5 Currently, it remains to be determined the origins and possible intermediate animal vectors of SARS-CoV-2, as well as the mechanism that this virus spread among humans. |
| T31 |
1133-1391 |
Sentence |
denotes |
Despite many reports have characterized the clinical, epidemiological, laboratory, and radiological features, as well as treatment and clinical outcomes of patients with COVID-19 pneumonia, the information of the SARS-CoV-2 reactivation remains not reported. |
| T32 |
1392-1469 |
Sentence |
denotes |
The curative and eradicative therapy for COVID-19 is not currently available. |
| T33 |
1470-1657 |
Sentence |
denotes |
Urgent questions that need to be addressed promptly include whether patients with COVID-19 pneumonia will reactivate, and whether risk factors predict SARS-CoV-2 reactivation in patients. |
| T34 |
1658-1806 |
Sentence |
denotes |
To prevent and control COVID-19 reactivation, we retrospectively collected and analyzed detailed clinical data from SARS-CoV-2 reactivated patients. |
| T35 |
1807-1955 |
Sentence |
denotes |
In the study, we presented clinical features of SARS-CoV-2 reactivated patients and discussed the potential risk factors of SARS-CoV-2 reactivation. |
